You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 16, 2025

CLINICAL TRIALS PROFILE FOR ACETAMINOPHEN


✉ Email this page to a colleague

« Back to Dashboard


505(b)(2) Clinical Trials for acetaminophen

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
OTC NCT00245375 ↗ A Trial Comparing Combination Therapy of Acetaminophen Plus Ibuprofen Versus Tylenol #3 for the Treatment of Pain After Outpatient Surgery Completed McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc. N/A 2005-01-01 Increasingly in general surgery, the investigators are conducting outpatient day surgery. Ambulatory surgery currently comprises 60 to 70% of surgeries performed in North America. These patients all require some form of analgesia which can be taken at home in the first few days after the surgery. The current standard at the investigators' centre and many others in the maritime provinces is to provide a prescription for oral acetaminophen plus codeine or oxycodone (Tylenol #3®, Percocet ®). Some patients may receive more potent opioids such as oral hydromorphone (Dilaudid®). Unfortunately, the most commonly prescribed medication (Tylenol #3®) is often poorly tolerated by patients, has several undesirable side effects, and may not provide effective pain relief. In the investigators' experience, non-steroidal anti-inflammatory drugs (NSAIDs) are uncommonly a routine addition to the home analgesic regimen. Tylenol #3®, in the investigators' experience and opinion, is a poor post surgical pain medication. They hope to show that a combination of ibuprofen and acetaminophen is better for pain relief after these procedures. The combination of acetaminophen and ibuprofen would be a safe, cheap, and readily available regimen. Unfortunately, as the prescribing practices of surgeons are old habits, it will require a very convincing argument to get them to change their practices. A randomized controlled trial comparing these two regimens, the investigators hope, would be a powerful enough argument. The hypothesis of this study, therefore, is that the pain control provided by a combination of acetaminophen plus ibuprofen (650 mg/400 mg four times per day) will be superior to Tylenol #3® (600 mg acetaminophen/60 mg codeine/15 mg caffeine four times per day). This study will attempt to enroll 150 patients in total. Eligible patients will be identified by their attending surgeon and contacted by study personnel. Patients who enroll in the study will undergo their surgery in the usual manner. After the surgery, in the recovery room, once they are ready to go home, they will be randomized to receive combination A or B and be given a week's worth of pain medication. They will then go home and take this medication as directed. They will record their pain intensity and pain relief once per day using a diary provided in the study package. One week after their surgery, they will return to the hospital clinic and be seen by the study nurse. They will hand over the diary and any unused medication. They will also be asked several questions regarding their overall satisfaction, incidence of side effects, and how long until they were pain free. The risks of participating in this study are minimal from the risks inherent to the procedures and medications the patients would receive within the standard of care. Ibuprofen is a commonly used NSAID which is widely available over the counter and has an established safety profile. The most common adverse effects of ibuprofen and other NSAIDs are gastrointestinal bleeding and ulceration. Other less common adverse effects include nephrotoxicity, hypersensitivity reactions, hepatic dysfunction (longterm use), and cognitive dysfunction. The investigators' patients will be selected to exclude those most at risk for these complications (see exclusion criteria). Acetaminophen has few side effects, with no adverse effects on platelet function and no evidence of gastric irritation.
OTC NCT00245375 ↗ A Trial Comparing Combination Therapy of Acetaminophen Plus Ibuprofen Versus Tylenol #3 for the Treatment of Pain After Outpatient Surgery Completed Nova Scotia Health Authority N/A 2005-01-01 Increasingly in general surgery, the investigators are conducting outpatient day surgery. Ambulatory surgery currently comprises 60 to 70% of surgeries performed in North America. These patients all require some form of analgesia which can be taken at home in the first few days after the surgery. The current standard at the investigators' centre and many others in the maritime provinces is to provide a prescription for oral acetaminophen plus codeine or oxycodone (Tylenol #3®, Percocet ®). Some patients may receive more potent opioids such as oral hydromorphone (Dilaudid®). Unfortunately, the most commonly prescribed medication (Tylenol #3®) is often poorly tolerated by patients, has several undesirable side effects, and may not provide effective pain relief. In the investigators' experience, non-steroidal anti-inflammatory drugs (NSAIDs) are uncommonly a routine addition to the home analgesic regimen. Tylenol #3®, in the investigators' experience and opinion, is a poor post surgical pain medication. They hope to show that a combination of ibuprofen and acetaminophen is better for pain relief after these procedures. The combination of acetaminophen and ibuprofen would be a safe, cheap, and readily available regimen. Unfortunately, as the prescribing practices of surgeons are old habits, it will require a very convincing argument to get them to change their practices. A randomized controlled trial comparing these two regimens, the investigators hope, would be a powerful enough argument. The hypothesis of this study, therefore, is that the pain control provided by a combination of acetaminophen plus ibuprofen (650 mg/400 mg four times per day) will be superior to Tylenol #3® (600 mg acetaminophen/60 mg codeine/15 mg caffeine four times per day). This study will attempt to enroll 150 patients in total. Eligible patients will be identified by their attending surgeon and contacted by study personnel. Patients who enroll in the study will undergo their surgery in the usual manner. After the surgery, in the recovery room, once they are ready to go home, they will be randomized to receive combination A or B and be given a week's worth of pain medication. They will then go home and take this medication as directed. They will record their pain intensity and pain relief once per day using a diary provided in the study package. One week after their surgery, they will return to the hospital clinic and be seen by the study nurse. They will hand over the diary and any unused medication. They will also be asked several questions regarding their overall satisfaction, incidence of side effects, and how long until they were pain free. The risks of participating in this study are minimal from the risks inherent to the procedures and medications the patients would receive within the standard of care. Ibuprofen is a commonly used NSAID which is widely available over the counter and has an established safety profile. The most common adverse effects of ibuprofen and other NSAIDs are gastrointestinal bleeding and ulceration. Other less common adverse effects include nephrotoxicity, hypersensitivity reactions, hepatic dysfunction (longterm use), and cognitive dysfunction. The investigators' patients will be selected to exclude those most at risk for these complications (see exclusion criteria). Acetaminophen has few side effects, with no adverse effects on platelet function and no evidence of gastric irritation.
OTC NCT00267293 ↗ Ibuprofen Alone and in Combination With Acetaminophen for Treatment of Fever Completed Children Youth and Family Consortium Phase 4 2006-01-01 Currently, when a child has fever either ibuprofen (e.g. Motrin, Advil) or acetaminophen (e.g. Tylenol) is given. Both Ibuprofen and Acetaminophen are approved for over the counter use for treatment of fever by the Food and Drug Administration (FDA). This study hopes to determine whether giving both medications together is better than giving one medication alone for the treatment of fever.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for acetaminophen

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000425 ↗ Toward Better Outcomes in Osteoarthritis Completed National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Phase 3 1996-07-01 This study will determine if there is a difference between commonly used nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen (a pain-reliever that does not prevent inflammation) for treating knee pain in osteoarthritis (OA). The two main results we will look at are disease progression according to x-rays and disability over 3.5 years. Study participants with moderate knee OA and knee pain will continue taking their NSAID or stop taking their NSAID and start taking acetaminophen. Every 6 months we will send the participants questionnaires that ask about pain, medication use, and disability. We will take x-rays of the knees at the start of the study and again at the end of the study.
NCT00000425 ↗ Toward Better Outcomes in Osteoarthritis Completed Stanford University Phase 3 1996-07-01 This study will determine if there is a difference between commonly used nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen (a pain-reliever that does not prevent inflammation) for treating knee pain in osteoarthritis (OA). The two main results we will look at are disease progression according to x-rays and disability over 3.5 years. Study participants with moderate knee OA and knee pain will continue taking their NSAID or stop taking their NSAID and start taking acetaminophen. Every 6 months we will send the participants questionnaires that ask about pain, medication use, and disability. We will take x-rays of the knees at the start of the study and again at the end of the study.
NCT00000491 ↗ Aspirin-Myocardial Infarction Study (AMIS) Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 3 1974-10-01 To determine whether the daily administration of 1 gm of aspirin to individuals with a documented myocardial infarction would result in a significant reduction in mortality over a three year period.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for acetaminophen

Condition Name

Condition Name for acetaminophen
Intervention Trials
Pain 134
Pain, Postoperative 103
Postoperative Pain 75
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for acetaminophen
Intervention Trials
Pain, Postoperative 264
Osteoarthritis 73
Acute Pain 58
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for acetaminophen

Trials by Country

Trials by Country for acetaminophen
Location Trials
United Kingdom 38
Egypt 34
Italy 32
France 30
Korea, Republic of 27
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for acetaminophen
Location Trials
Texas 169
California 144
New York 138
Pennsylvania 100
Florida 90
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for acetaminophen

Clinical Trial Phase

Clinical Trial Phase for acetaminophen
Clinical Trial Phase Trials
Phase 4 417
Phase 3 218
Phase 2/Phase 3 31
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for acetaminophen
Clinical Trial Phase Trials
Completed 679
Recruiting 186
Not yet recruiting 117
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for acetaminophen

Sponsor Name

Sponsor Name for acetaminophen
Sponsor Trials
M.D. Anderson Cancer Center 43
Mallinckrodt 28
Montefiore Medical Center 17
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for acetaminophen
Sponsor Trials
Other 1354
Industry 430
NIH 82
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Acetaminophen: Clinical Trials, Market Analysis, and Projections

Introduction to Acetaminophen

Acetaminophen, commonly known as paracetamol, is a widely used analgesic and antipyretic drug. It is employed to alleviate discomfort in mild to moderate headaches, toothaches, colds, and various other pain-related conditions. Here, we will delve into recent clinical trials, market analysis, and future projections for acetaminophen.

Clinical Trials Update

Acetaminophen in Sepsis

Recent clinical trials have explored the potential of acetaminophen in treating sepsis, a life-threatening condition that arises when the body's response to infection causes injury to its own tissues and organs.

  • A NIH-supported clinical trial, known as the Acetaminophen and Ascorbate in Sepsis: Targeted Therapy to Enhance Recovery (ASTER) trial, was conducted from October 2021 to April 2023. This phase 2b randomized, double-blind trial involved 447 adults with sepsis and respiratory or circulatory organ dysfunction. Patients were randomized to receive either intravenous acetaminophen or a placebo every six hours for five days. The results showed that while acetaminophen was safe, it did not significantly improve days alive and free of organ support in critically ill sepsis patients[1][4].

  • However, the study suggested that acetaminophen might hold promise for the most critically ill patients, particularly those with higher levels of cell-free hemoglobin. Researchers plan to conduct a larger clinical trial focusing on these patients[1].

Safety and Efficacy

The trials highlighted that intravenous acetaminophen is safe, with no significant differences in liver enzymes, hypotension, or fluid balance between the treatment and placebo groups. However, the primary outcome of days alive and free of organ support to day 28 was not meaningfully different between the acetaminophen and placebo groups[4].

Market Analysis

Global Market Size and Growth

The global acetaminophen market is substantial and growing. Here are some key statistics:

  • As of 2024, the global acetaminophen market size was valued at approximately USD 10.83 billion and is expected to reach USD 19.19 billion by 2037, growing at a CAGR of more than 4.5% during the forecast period[2].

  • Another report estimates the global acetaminophen market size to be USD 10,251.5 million in 2024, projected to grow at a CAGR of 4.5% to reach USD 13,950.87 million by 2031[5].

Regional Market Share

The market is distributed across various regions, each with its own growth trajectory:

  • North America: Held the largest share of the global acetaminophen market in 2021, with a market size of USD 4,100.60 million in 2024. It is expected to grow at a CAGR of 2.7% from 2024 to 2031[5].

  • Europe: Accounted for more than 30% of the global revenue, with a market size of USD 3,075.45 million in 2024, and is expected to grow at a CAGR of 3.0% from 2024 to 2031[5].

  • Asia Pacific: Held around 23% of the global revenue, with a market size of USD 2,357.85 million in 2024. This region is expected to grow at a CAGR of 6.5% from 2024 to 2031, driven by increasing population and health issues[5].

  • Latin America and Middle East & Africa: These regions also contribute to the global market, with Latin America holding around 5% and the Middle East & Africa holding around 2% of the global revenue in 2024[5].

Sales Channels and Product Forms

  • The oral route of administration dominates the market, accounting for 92.4% of the total market share in 2021. Over-the-counter (OTC) sales accounted for 91.6% of the global market share in the same year[3].

  • Sales through retail pharmacies are significant, accounting for 28.5% of the total market share in 2021. The market is also driven by the availability of acetaminophen in combination with other pain-relieving drugs[3].

Growth Drivers and Challenges

Growth Drivers

  • Increasing Population and Health Issues: The global population is growing at a rate of nearly 1% annually, leading to an increased demand for healthcare products, including acetaminophen[2].

  • Chronic Pain Prevalence: High chronic pain rates, especially in regions like Asia Pacific where 25.9% of the population experiences chronic pain daily, drive the demand for acetaminophen[2].

  • Government Health Campaigns: Public health campaigns aimed at increasing health awareness and making quality healthcare accessible further boost the market[2].

Challenges

  • Competition from Generic Medications: The availability of generic acetaminophen, particularly in regions like China, poses a challenge due to stiff competition among manufacturers[2].

  • Healthcare System Strain: The growing pharmaceutical demands in densely populated regions can strain the healthcare system, making it challenging to meet the increasing needs[2].

Future Projections

Market Expansion

The acetaminophen market is expected to continue growing due to the increasing prevalence of pain-related conditions and the expanding global population. By 2037, the market is projected to reach USD 19.19 billion, with a CAGR of more than 4.5% during the forecast period[2].

Regional Growth

  • Asia Pacific: This region is expected to dominate over 32% of the revenue share by 2037, driven by the increasing population and health issues[2].

  • North America and Europe: These regions will continue to hold significant market shares, though with slower growth rates compared to Asia Pacific[5].

Key Takeaways

  • Clinical Trials: Recent trials indicate that while intravenous acetaminophen is safe, it does not significantly improve outcomes for all sepsis patients but shows promise for the most critically ill.
  • Market Size: The global acetaminophen market was valued at approximately USD 10.83 billion in 2024 and is expected to grow to USD 19.19 billion by 2037.
  • Regional Growth: Asia Pacific is expected to dominate the market, driven by population growth and health issues.
  • Growth Drivers: Increasing population, chronic pain prevalence, and government health campaigns are key drivers.
  • Challenges: Competition from generic medications and strain on healthcare systems are significant challenges.

FAQs

What are the recent findings on using acetaminophen in sepsis patients?

Recent clinical trials, such as the ASTER trial, have shown that intravenous acetaminophen is safe but does not significantly improve days alive and free of organ support in critically ill sepsis patients. However, it may hold promise for the most critically ill patients with higher levels of cell-free hemoglobin[1][4].

What is the current global market size of acetaminophen?

The global acetaminophen market size was valued at approximately USD 10.83 billion in 2024[2].

Which region is expected to dominate the acetaminophen market in the future?

The Asia Pacific region is expected to dominate over 32% of the revenue share by 2037, driven by the increasing population and health issues[2].

What are the primary growth drivers for the acetaminophen market?

The primary growth drivers include the increasing global population, high chronic pain rates, and government health campaigns aimed at increasing health awareness and making quality healthcare accessible[2].

What challenges does the acetaminophen market face?

The market faces challenges such as competition from generic medications, particularly in regions like China, and the strain on healthcare systems due to growing pharmaceutical demands[2].

How is the acetaminophen market segmented?

The market is segmented by product type, route of administration, and sales type. The oral route of administration dominates, and OTC sales account for a significant portion of the market[3].

Sources

  1. National Institutes of Health: "Acetaminophen shows promise in warding off acute respiratory distress syndrome, organ injury in patients with sepsis" - May 21, 2024.
  2. Research Nester: "Acetaminophen Market Size & Share, Growth Trends 2037" - November 15, 2024.
  3. GlobeNewswire: "Acetaminophen Market to be worth US$ 14.07 Billion by the year 2031" - March 6, 2022.
  4. Epocrates: "ATS 2024: No mortality benefit for IV acetaminophen in sepsis" - May 22, 2024.
  5. Cognitive Market Research: "The global Acetaminophen market size will be USD 10251.5 million in 2024" - 2024.

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.